Critical Comparison: Sight Sciences (NASDAQ:SGHT) versus Sharps Technology (NASDAQ:STSS)

Sharps Technology (NASDAQ:STSS) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Earnings & Valuation

This table compares Sharps Technology and Sight Sciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sharps Technology	N/A	N/A	-$9.84 million	($0.60)	-4.82
Sight Sciences	$79.40 million	3.74	-$55.55 million	($1.12)	-5.33

Sharps Technology has higher earnings, but lower revenue than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

17.2% of Sharps Technology shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 12.6% of Sharps Technology shares are owned by company insiders. Comparatively, 28.9% of Sight Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Sharps Technology and Sight Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sharps Technology	N/A	-100.69%	-71.53%
Sight Sciences	-65.90%	-45.68%	-32.27%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Sharps Technology and Sight Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sharps Technology	0	0	0	0	N/A
Sight Sciences	0	4	1	0	2.20

Sight Sciences has a consensus price target of $7.25, indicating a potential upside of 21.44%. Given Sight Sciences’ higher possible upside, analysts plainly believe Sight Sciences is more favorable than Sharps Technology.

Risk & Volatility

Sharps Technology has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500.

Summary

Sight Sciences beats Sharps Technology on 8 of the 12 factors compared between the two stocks.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

About Sight Sciences

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.